Akebia Therapeutics, Inc. (NASDAQ:AKBA) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Wednesday.

AKBA has been the subject of a number of other research reports. UBS AG reiterated a “buy” rating and set a $17.00 target price (up previously from $12.00) on shares of Akebia Therapeutics in a research note on Friday, May 5th. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Akebia Therapeutics in a research note on Tuesday, June 6th. Needham & Company LLC reiterated a “buy” rating and set a $21.00 target price (up previously from $18.00) on shares of Akebia Therapeutics in a research note on Wednesday, May 17th. JMP Securities boosted their target price on shares of Akebia Therapeutics from $19.00 to $21.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 26th. Finally, Zacks Investment Research downgraded shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $18.25.

Akebia Therapeutics (NASDAQ AKBA) traded up 1.10% during mid-day trading on Wednesday, hitting $13.82. The stock had a trading volume of 433,208 shares. The firm has a 50-day moving average of $14.38 and a 200-day moving average of $11.50. The stock’s market cap is $252.91 million. Akebia Therapeutics has a 52-week low of $7.16 and a 52-week high of $16.54.

Akebia Therapeutics (NASDAQ:AKBA) last issued its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by $1.00. The company had revenue of $20.87 million for the quarter, compared to analysts’ expectations of $16.50 million. On average, analysts forecast that Akebia Therapeutics will post ($3.46) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/07/23/bidaskclub-downgrades-akebia-therapeutics-inc-nasdaqakba-to-sell.html.

In related news, Director Muneer A. Satter acquired 1,034,482 shares of the firm’s stock in a transaction on Wednesday, July 5th. The stock was bought at an average price of $14.50 per share, for a total transaction of $14,999,989.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 7.95% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Eagle Asset Management Inc. increased its position in Akebia Therapeutics by 1.5% in the first quarter. Eagle Asset Management Inc. now owns 3,550,547 shares of the biopharmaceutical company’s stock valued at $32,665,000 after buying an additional 51,190 shares in the last quarter. First Manhattan Co. increased its position in Akebia Therapeutics by 64.2% in the first quarter. First Manhattan Co. now owns 1,705,300 shares of the biopharmaceutical company’s stock valued at $15,432,000 after buying an additional 666,800 shares in the last quarter. Vanguard Group Inc. increased its position in Akebia Therapeutics by 8.8% in the first quarter. Vanguard Group Inc. now owns 1,301,880 shares of the biopharmaceutical company’s stock valued at $11,977,000 after buying an additional 105,645 shares in the last quarter. Morgan Stanley increased its position in Akebia Therapeutics by 6.8% in the first quarter. Morgan Stanley now owns 870,442 shares of the biopharmaceutical company’s stock valued at $8,008,000 after buying an additional 55,369 shares in the last quarter. Finally, MARSHALL WACE ASIA Ltd bought a new position in Akebia Therapeutics during the first quarter valued at about $6,232,000. Institutional investors own 48.21% of the company’s stock.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.